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Abstract
Purpose The tracer
123I-2-([2-({dimethylamino}methyl)
phenyl]thio)-5-iodophenylamine ([
123I]ADAM) has been
developed to image serotonin transporters (SERTs) with
SPECT. Preclinical studies have shown that [
123I]ADAM
binds selectively to SERTs. Moreover, initial human studies
have shown that [
123I]ADAM binding could be blocked by
selective serotonin reuptake inhibitors (SSRIs). However, in
humans it has not been proven that [
123I]ADAM binds
selectively to SERTs.
Methods WeexaminedtheinvivoavailabilityofSERTsin12
healthy young volunteers 5 h after bolus injection of [
123I]
ADAM. To evaluate the selectivity of binding, four
participants were pretreated (double-blinded design) with
placebo, four with paroxetine (20 mg) and four with the
dopamine/norepinephrine blocker methylphenidate (20 mg).
SPECT studies were performed on a brain-dedicated system
(Neurofocus), and the SPECT images were coregistered with
individual MR scans of the brain. ADAM binding in SERT-
rich brain areas and cerebellar cortex (representing non-
specific binding) was assessed by drawing regions of interest
(ROIs) on the individual MR images. Specific to non-
specific ratios were used as the outcome measure.
Results We found that specific to non-specific ratios were
statistically significantly lower in paroxetine-pretreated
participants than in placebo- or methylphenidate-pretreated
participants. No such difference was found between groups
pretreated with placebo or methylphenidate.
Conclusion Our preliminary findings suggest that [
123I]
ADAM binds selectively to SERTs in human brain.
Keywords Serotonin transporter imaging.SPECT.
[
123I]ADAM.Human.Selectivity
Introduction
Serotonin transporters (SERTs) are located in the membrane
of serotonergic neuron terminals and play an important role in
the regulation of serotonin in the synaptic cleft. They are
believed to be the primary target for antidepressants, such as
selective serotonin reuptake inhibitors (SSRIs) [1]. Distur-
bances in the expression of central SERTs are thought to play
an important role in psychiatric disorders, such as major
depression.
In vivo imaging of SERTs with PET or SPECT provides
an important tool to study the availability of SERTs in
living human brain. Recently, the diarylsulphide derivative
[
123I]-2-([2-({dimethylamino}methyl)phenyl]thio)-5-iodo-
phenylamine ([
123I]ADAM) has been developed to image
SERTs with SPECT. Studies in small laboratory animals
and non-human primates have shown that the in vivo
binding of [
123/125I]ADAM is selective for SERTs [2, 3]. In
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radiotracer binding in SERT-rich brain areas could be
blocked by SSRIs [4, 5]. However, it has not been proven
that [
123I]ADAM binds selectively to SERTs in living
human brain.
Therefore, the purpose of the current study was to
evaluate whether [
123I]ADAM binds selectively to SERTs
in living human brain.
Materials and methods
Subjects
Twelve healthy male volunteers were included in the
present study. Exclusion criteria were age below 18 or
above 35 years, major mental or physical problems, use of
psychopharmaceuticals such as SSRIs and use of hard
drugs such as ecstasy, cocaine, amphetamine or heroin in
the past. To exclude a clinical depression, all volunteers had
to complete the Beck Depression Inventory (BDI), a
validated self-report depression questionnaire. Written
informed consent was obtained from all subjects and the
study was approved by the local Medical Ethics Commit-
tee. In addition, we received permission from local
competent authorities to administer radiation to young
healthy subjects.
Pretreatment of participants
To evaluate the selectivity of [
123I]ADAM binding to
SERTs, four participants were pretreated with placebo
(one tablet), four participants with the SSRI paroxetine
(20 mg) and four with the dopamine/norepinephrine
blocker methylphenidate (20 mg, immediate release). To
guarantee accurate intake of the tablets, the intake was
supervised by an independent person. Dosing was based on
the following arguments: a single dose of each drug is well
tolerated, and 20 mg paroxetine is able to block >70% of
central SERTs, and one dose of 20 mg methylphenidate
(immediate release) is able to occupy 55% of dopamine
transporters in the striatum [6, 7]. The tablets were always
administered orally 2.5 h prior to injection of [
123I]ADAM,
using a double-blind study approach. The participants were
not allowed to eat after midnight, and they received the
tablets always around 08.00 a.m. Two hours after intake of
the tablet, the participants were allowed to eat.
[
123I]ADAM SPECT experiments
Subjects were examined using SPECT with the ligand [
123I]
ADAM. Radiosynthesis of [
123I]ADAM was performed at
MAP Medical Technologies Oy (Tikkakoski, Finland). The
123I-labelled ADAM was prepared by iododestannylation of
the corresponding trimethyltin precursor, with carrier-free
123I as NaI. The radiochemical purity of the solution was
always higher than 95.0%. [
123I]ADAM was injected
intravenously as a bolus (140.6±6.6 MBq = mean ± SD).
Subjects received a potassium iodide solution to block
thyroid uptake of free radioactive iodide.
SPECT study
SPECT studies were always acquired 5 h after injection of
the radiotracer [8]. They were performed using a 12-
detector single-slice brain-dedicated scanner (Neurofocus
810, which is an upgrade of the Strichmann Medical
Equipment) with a full-width at half-maximum (FWHM)
resolution of approximately 6.5 mm throughout the 20-cm
field of view (http://www.neurophysics.com). In this study,
the energy window was set at 135–190 keV. Attenuation
correction of all images was performed as earlier described
(see references in [8]). Images were reconstructed in 3-D
mode.
MRI study
For anatomical reference, in each individual T1-weighted 3-
D MRI was performed using a 3-T Philips Intera scanner
(Philips Healthcare, Best, The Netherlands) with a standard
head coil.
Image analysis
For the analysis of SERT availability, regions of interest
(ROIs) were drawn manually on each individual T1-
weighted 3-D MRI scan for the midbrain and thalamus,
which are SERT-rich regions, and for the cerebellar cortex
(Fig. 1), which was assumed to represent non-displaceable
activity and therefore could be used as reference region. ROIs
weredrawn on the MRI scan bymakinguse ofself-developed
software [9]. The volumes of the ROIs were not statistically
significantly different between groups. By means of the same
program, we matched the SPECT scans of the subjects with
their individual T1-weighted 3-D MRI scans and extracted
SERT availability of the respective ROIs. Specific to non-
specific binding ratios for SERT were calculated: (activity in
ROI minus activity in cerebellar cortex)/activity in cerebellar
cortex.
Statistical analysis
A Mann-Whitney U test was used to detect differences in
specific to non-specific ratios of [
123I]ADAM binding
between groups. In the statistical analysis, which was two-
tailed, p<0.05 was considered significant.
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Subjects
The mean age of the male subjects was 22.7±2.7 years
(mean ± SD; range: 19–29 years). The mean BDI scores
were 0.4±0.8 (range: 0–2). As BDI scores between 0 and 9
are regarded as normal, none of the subjects was suspected
of having clinical depression.
SPECT measures
The specific to non-specific ratios in the midbrain were
statistically significantly lower in the group that was pre-
treated with paroxetine (mean ± SD: 0.24±0.55) than in the
placebo- (0.93±0.27) or methylphenidate-pretreated group
(1.13±0.31; p=0.042 and 0.043, respectively; Fig. 2). These
ratios in the midbrain were not statistically significantly
different between the placebo- and methylphenidate-
pretreated groups (p=0.375).
The specific to non-specific ratios in the thalamus area
were statistically significantly lower in the paroxetine-
pretreated group (mean ± SD: 0.00±0.21) than in the
placebo- (0.46±0.07) or methylphenidate-pretreated groups
(0.76±0.30; p=0.021 and 0.021, respectively; Fig. 2). These
ratios in the thalamus were not significantly different
between the placebo- and the methylphenidate-pretreated
groups (p=0.149).
Discussion
To the best of our knowledge, the present preliminary
study is the first to show that [
123I]ADAM binds
Fig. 1 a Transverse SPECT image obtained 5 h after injection of
approximately 140 MBq [
123I]ADAM at the level of the midbrain. b
Transverse T1-weighted MRI image of the same subject with ROI
drawn in the midbrain. c Coregistered SPECT and T1-weighted MRI
image with ROI drawn in the midbrain. d Transverse SPECT image
(5 h post-injection) at the level of the thalamus. e Transverse T1-
weighted MRI image of the same subject with ROI drawn in the
thalamus. f Coregistered SPECT and T1-weighted MRI image with
ROI drawn in the thalamus. The SPECT images are colour encoded
for low (black) to high activity (white)
Eur J Nucl Med Mol Imaging (2010) 37:1507–1511 1509selectively to SERTs in living human brain. We were able
to show this selectivity, since healthy male controls pre-
treated with an SSRI (paroxetine) had significantly lower
[
123I]ADAM binding to SERTs than participants pretreated
with placebo or the dopamine/norepinephrine blocker meth-
ylphenidate, while [
123I]ADAM binding did not significantly
differ between the placebo- and methylphenidate-pretreated
participants. This was true both for [
123I]ADAM binding in
the SERT-rich thalamus as well as in the SERT-rich
midbrain. This result validates the use of [
123I]ADAM as a
selective tracer for the SERT in human studies and is
complementary to results obtained in ex vivo rat studies and
in vivo experiments in non-human primates [2, 3].
In this study, we found high specific binding of [
123I]
ADAM in the thalamus and midbrain. This finding is in
line with a previous PET study using selective tracers for
the SERT [10] and human necropsy studies [11].
Strengths of our study are its design (placebo-controlled,
double-blind), coregistration of the SPECT images with
individual MR images and use of the cerebellar grey matter
cortex as a reference region. Indeed, one has to keep in mind
that the cerebellar vermis is not devoid of SERTs [12].
Besides, several limitations of the current study should be
discussed. First, only young men were included. However, it
islikelythatourpresentfindingscouldbegeneralizedtoolder
men and are gender independent. Second, a small group was
studied. This small sample size limits the statistical power of
our results, and therefore our results should be interpreted as
preliminary and are in need of replication. Third, with our
study protocol only [
123I]ADAM binding to SERTs can be
measured accurately in SERT-rich brain areas. We can
therefore not prove that binding of ADAM is also selective
for SERT in brain areas expressing low densities of SERTs.
In the present study, single SPECT scans were acquired
during transient equilibrium 5 h after bolus injection of the
tracer. This time point was based on the results of a
previous study, performed in young adults, in which the
mean ratio of specific to non-specific [
123I]ADAM binding
was highest in SERT-rich areas at 5 h post-injection [8]. A
recent study [5], however, showed that the ratio method,
when based on time frames from 200–240 min or 240–
280 min after injection of [
123I]ADAM, slightly, but
statistically significantly overestimated specific binding in
humans, and particularly in brain regions expressing high
densities of SERTs (by 10% on average). This overestima-
tion is consistent with theoretic predictions that the ratio of
specific binding to non-specific binding during transient
equilibrium overestimates the ratio at true equilibrium.
Consequently, we can not exclude that particularly in the
placebo- and methylphenidate-pretreated groups the specif-
ic binding ratios were slightly overestimated (on average
10%). However, given the large difference in binding ratios
between the paroxetine-pretreated group and the placebo-
and methylphenidate-pretreated groups (see Fig. 2), it is
likely that when [
123I]ADAM binding to SERT will be
measured at true equilibrium similar results can be found.
[
123I]ADAM binding was higher after methylphenidate
pretreatment than after placebo pretreatment, particularly in
the thalamus. Although this difference was not statistically
significant, and should be described at best as a possible
trend, it may be of interest to investigate in further studies
whether acute intervention with methylphenidate might
influence the expression of SERTs, since direct interactions
between the central dopaminergic and serotonergic neuro-
transmission systems are well known [13]. Previous animal
studies, using ADAM as a SPECT or PET tracer, however,
did not show statistically significant effects of pretreatment
with methylphenidate on ADAM binding [2, 3, 14]. For
example, a SPECT study performed in non-primates by Ma
and co-workers [3] found no statistically significant effects
Fig. 2 Individual and mean specific to non-specific [
123I]ADAM binding ratios (BPND) in the midbrain and thalamus per pretreatment group.
BPND binding potential non-displaceable
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weight) on specific uptake ratios of [
123I]ADAM in the
SERT-rich midbrain and thalamus, and these ratios were
even lower than ratios obtained in the control condition at
most time points of the SPECT measurements.
In this study, a single dose of 20 mg paroxetine was used
to evaluate binding to SERTs in healthy controls. In the
present study this dose induced an occupancy of >70% of
SERTs in the midbrain and thalamus (specific ratios in the
paroxetine-pretreatedgroupcomparedtothose obtainedinthe
placebo-pretreated group). A SERT PETstudy by Meyer and
co-workers [7] showed that treatment with 20 mg/day of
paroxetine for a 4-week period in depressed patients showed
a mean proportion of SERT occupied by paroxetine of 83%.
In addition, they showed that SERToccupancy increased in a
non-linear relationship with serum levels of paroxetine. After
intake of one dose of oral paroxetine by healthy subjects,
plasma levels are highly variable between subjects, with a
mean plasma level of approximately 8 µg/l 3 h after oral
intake of the tablet [15]. Interestingly, the reported relation-
ship of paroxetine SERT occupancy with serum levels as
described by Meyer and co-workers [7] predicted that a
plasma paroxetine level of 8 µg/l will induce an occupancy
of approximately 70% of SERTs, which is in agreement with
our present finding, although a limitation of the present study
was that we did not measure plasma levels of paroxetine.
In conclusion, in this preliminary double-blind, placebo-
controlled study we show that in vivo [
123I]ADAM binding
to SERT is selective in young healthy men.
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